Six details:
1. Full-year 2020 net sales are expected to be $407 million, representing a 12 percent decrease year over year.
2. For the fourth quarter, spinal implants net sales increased 11 percent, to $28 million, and biologics sales decreased 9 percent to $15 million, compared to the same period in 2019.
3. Orthofix attributed the rise in spinal implants sales to the adoption of its M6-C artificial cervical disc.
4. Motion preservation net sales in the fourth quarter are expected to rise 129 percent year over year to $7 million.
5. As of Dec. 31, cash, cash equivalents, and restricted cash was $96 million to $97 million, compared to $70 million on Dec. 31, 2019.
6. Orthofix will report full-year 2020 financial results and provide its financial outlook for 2021 in late February.
More articles on devices:
Medtronic CEO predicts AI, machine learning as ‘the new frontier for medtech’ — 4 key quotes
40 orthopedic devices receiving FDA clearance in December
Stryker, Smith+Nephew seal 1st acquisitions of 2021: 7 device company notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.